Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Kudlow also confirmed to CNBC that he supported a tax cut proposal floated earlier Thursday by Sen. Rick Scott, R-Fla.Politicsread more
VMware is following through on its proposal to buy Pivotal, a fellow Dell subsidiary, and expanding into cybersecurity with the acquisition of Carbon Black.Technologyread more
Google says it shut down hundreds of YouTube channels tied to misinformation around the Hong Kong protests.Technologyread more
It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Investors are rushing to get a piece of its privately held rival Impossible Foods before it goes public, according to the Wall Street Journal.Food & Beverageread more
Weisler has been CEO at the company since 2015 when it split from HPE.Technologyread more
Apple CEO Tim Cook has found the "recipe" for a positive relationship with the president, management expert Jeffrey Sonnenfeld told CNBC on Thursday.Politicsread more
Citron Research Executive Editor Andrew Left said Tuesday he does not think Valeant Pharmaceutical shares will trade above $60 anytime soon, despite taking a long position in the stock.
"You still might say the stock is uninvestable," he told CNBC's "Fast Money: Halftime, " a day after unveiling his new position on the stock.
"I bought some stock [in Valeant]; I also protected myself and bought some out-of-the-money puts. I also saw the news flow that was coming out of Valeant was increasingly negative, and when they installed [CEO Joseph] Papa, he didn't seem like somebody getting the company ready for bankruptcy. Whether or not the stock can stabilize around here, it seemed like something that could've made a decent proposition," he said. "Would I hold this for the next 18 months? I'd need more information on it."
Shares of Valeant were up more than 8 percent before Left's interview, but quickly pared some of those gains afterward.
Citron first unveiled a short position on Valeant in October, calling it the "pharmaceutical Enron."
Since then, Valeant's U.S.-listed shares have fallen more than 75 percent.
VRX Oct. 21-nowSource: FactSet
In March, Left told CNBC he had covered the short position, adding: "I wouldn't be short Valeant, I wouldn't be long Valeant. I think there's just too much of a black box surrounding Valeant right now. I would like to get more information."